HealthQuill Bone Marrow
Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before, and the disease has recurred, has received the US regulator’s green light.
Drugs Health Pharma

Regenron’s drug to treat a type of blood cancer gets US regulator’s nod

HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.

Read More
A third of patients with a type of blood cancer, especially those whose disease had returned or not responded to other treatments, have shown “promising” results in an early Johnson & Johnson trial.
Drugs Health Pharma

A third of blood cancer cases in J&J trials live without detectable cancer 

HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not.

Read More
France’s Sanofi SA will acquire US-based Blueprint Medicines Corporation for $9.1 billion to gain access to an immunology medicine for a rare disease and expand the company’s portfolio.
Drugs Health Pharma

Sanofi to acquire Blueprint for $9.1b for immunology medicine

HQ Team June 2, 2025: France’s Sanofi SA will acquire US-based Blueprint Medicines Corporation for $9.1 billion to gain access to an immunology.

Read More
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.
Drugs Health Pharma

US drug regulator blocks Regeneron’s blood cancer therapy 

The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.

Read More
Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli.
Drugs Health Pharma

Johnson & Johnson’s blood cancer medicine cleared for bi-weekly use

HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.

Read More